Osteosarcoma Conventional treatment vs. gene therapy

被引：91

作者：

Tan, Mei Lin ^{[1
,2
]}

Choong, Peter F. M. ^{[1
,2
,3
]}

Dass, Crispin R. ^{[1
,2
]}

机构：

[1] Univ Melbourne, St Vincents Hosp Melbourne, Dept Orthopaed, Fitzroy, Vic 3065, Australia

[2] Univ Melbourne, St Vincents Hosp Melbourne, Dept Surg, Fitzroy, Vic 3065, Australia

[3] Peter MacCallum Canc Inst, Bone & Soft Tissue Sarcoma Serv, Melbourne, Vic 3000, Australia

来源：

CANCER BIOLOGY & THERAPY | 2009年 / 8卷 / 02期

关键词：

osteosarcoma; treatment; gene therapy; surgery; chemotherapy; radiotherapy; EPITHELIUM-DERIVED FACTOR; CHITOSAN-DNA NANOPARTICLES; HIGH-GRADE OSTEOSARCOMA; HIGH-DOSE METHOTREXATE; SMALL INTERFERING RNA; IN-VIVO; ANTHRACYCLINE CARDIOTOXICITY; OLIGONUCLEOTIDE DELIVERY; COMBINATION CHEMOTHERAPY; NEOADJUVANT CHEMOTHERAPY;

D O I：

10.4161/cbt.8.2.7385

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Osteosarcoma (OS) remains the most common primary malignant bone cancer affecting children and adolescents. Majority of patients are subjected to surgery and chemotherapy with limited alternatives to consider. However, with increasing knowledge of the molecular pathogenesis of OS, advancements in OS therapy research fields have developed potential agents for a more targeted and localised approach to treatment. Thus, this review attempts to examine some common treatment strategies (surgery, radiotherapy and chemotherapy) employed clinically as well as recent developments in newer experimental therapy methods (gene therapy) which might potentially benefit patients.

引用

页码：106 / 117

页数：12

共 156 条

[11] Cell proliferation, apoptosis and mitochondrial damage in rat B50 neuronal cells after cisplatin treatment [J].